Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Temozolomide or Etoposide for Recurrent GBM
NCT00613028Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2008
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by Duke University. Primary endpoint: 6 Month Progression-free Survival. Started Apr 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00613028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613028.